breaking news - update 2

BioClinica and CCBR-Synarc to merge with Water Street, JLL and Ampersand sharing ownership

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Medicine, Mergers and acquisitions, Drug development, Bioclinica

BioClinica and CCBR-Synarc to merge
BioClinica and CCBR-Synarc to merge
BioClinica and CCBR-Synarc have agreed to merge with Water Street, JLL and Ampersand sharing ownership.

The agreement - financial terms of which were not disclosed - will see Bioclinica – which is owned by JLL Partners and Ampersand Capital Partners​ – combine with imaging services firm CCBR-Synarc, which was acquired by Water Street last April​.

A spokeswoman for Water Street told that: "Water Street, JLL and Ampersand will all have ownership positions in the merged business. By bringing their companies together, CCBR-SYNARC and BioClinica will offer customers a comprehensive suite of services specializing in increasing the speed and efficiency of global clinical trials. 

She added that: "CCBR-SYNARC will add patient recruitment services and medical imaging for the neurology and musculoskeletal therapeutic areas to BioClinica. BioClinica will bring to CCBR-SYNARC medical imaging services for oncology, as well as consulting services and technology to support the overall drug development process. The integration process is underway and the transaction is expected to close by the end of the first quarter​."

In a statement issued today the firms said: “This merger comes at a time when demand for outsourced pharmaceutical services isprojected to grow more than five percent per year over the next five years."

CCBR-Synarc is composed of two companies. California, US-headquartered Synarc provides trial imaging services, while Denmark-based CCBR focuses on patient recruitment.

The addition of CCBR-Synarc's medical imaging capabilities to Bioclinica's exisiting offering is in keeping with JLLs decision to merge the firm with CoreLab, which it also acquired in January 2012​. 

Jeffrey McMullen, vice chairman of inVentiv Health, has been appointed chairman of the merged company 


BioClinica CEO Mark Weinstein - who will lead the new merged organisation - has been an advocate of expanding the firm's offoring through bolt on acqusitions over the last few years​.

In 2012 he told that: “There are many facets of the clinical development process and we are always looking to be acquisitive for systems and services that would be additive to what we have today.”

“As we implement a truly unified clinical development platform there will definitely be pieces that we can add, but with that said, we believe we have the core components now and will continue to be focused on driving results for our customers,”​ he said. “It is a good situation to be in."

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers